<DOC>
	<DOCNO>NCT00516243</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose define green tea catechin extract treat woman hormone receptor-negative stage I-III breast cancer . Green tea extract contain ingredient may prevent slow growth breast cancer .</brief_summary>
	<brief_title>Defined Green Tea Catechin Extract Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Demonstrate safety green tea catechin extract ( Polyphenon E ) woman history hormone receptor-negative breast cancer . II . Determine maximum tolerate dose Polyphenon E woman history hormone receptor-negative breast cancer . SECONDARY OBJECTIVES : I . Determine efficacy Polyphenon E modulate histologic change ( nonproliferative , proliferative without atypia , atypical hyperplasia ) core biopsy contralateral breast . II . Determine efficacy Polyphenon E modulate immunohistochemical expression Ki-67 ( proliferation index ) , p53 , EGFR , HER2/neu , cleave caspase-3 ( apoptosis marker ) , estrogen receptor core biopsy tissue contralateral breast . III . Determine efficacy Polyphenon E modulate mammographic breast density contralateral breast . IV . Determine efficacy Polyphenon E modulate hormone metabolite ( serum estradiol , testosterone , IGF-1 , IGFBP-3 , SHBG ) . V. Determine efficacy Polyphenon E modulate eicosanoid level ( urine PGE-M ) . VI . Determine efficacy Polyphenon E modulate biomarkers oxidative damage ( urine 8-OHdG , isoprostane ) . VII . Determine efficacy Polyphenon E modulate serum C-reactive protein . VIII . Determine activity Polyphenon E relation COMT genotype . IX . Assess quality life attitude toward complementary alternative medicine woman history breast cancer . OUTLINE : This dose-escalation study . Patients randomize 1 2 treatment arm . ARM I : Patients receive define green tea catechin extract orally ( PO ) twice daily ( BID ) 6 month absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO BID 6 month absence disease progression unacceptable toxicity . Patients undergo core biopsy mammogram contralateral breast baseline 6 month histological evaluation , IHC analysis , mammographic density reading . Core biopsy tissue assess proliferative change presence atypia use standardized histological criterion . Core biopsy tissue also analyze IHC follow protein : Ki-67 ( proliferation index ) , p53 , EGFR , HER2/neu , cleave caspase-3 ( apoptosis marker ) , estrogen receptor ( ER ) . Blood urine sample collect baseline every 2 month treatment measure drug effect biomarkers : serum estradiol , testosterone , insulin-like growth factor-1 ( IGF-1 ) , IGF bind protein-3 ( IGFBP-3 ) , sex hormone-binding globulin ( SHBG ) immunological laboratory method ; urine prostaglandin level ( PGE-M ) tandem mass spectrometry ; urine oxidative damage marker ( 8-OHdG , isoprostane ) serum C-reactive protein ( CRP ) ELISA ; catechol-O-methyltransferase ( COMT ) genotype ( baseline ) . Patients complete questionnaire assess quality life ( SF-36 ) attitudes toward complementary alternative medicine baseline 6 month . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Criteria : History histologically confirm stage I , II , III breast carcinoma without evidence disease study entry No evidence recurrent disease ( patient resect local recurrence eligible ) Normal mammogram contralateral breast within past 12 month , define new suspicious calcification abnormal finding warrant breast biopsy No history histologically confirm bilateral breast cancer No evidence metastatic breast cancer Registered outpatient medical oncology clinic Columbia University Medical Center ( CUMC ) , MD Anderson Cancer Center ( MDACC ) , Memorial Sloan Kettering Cancer Center ( MSKCC ) , WeillCornell campus New York Presbyterian Hospital ( NYPWC ) Hormone receptor status : Estrogen progesteronereceptor negative Menopausal status : Pre postmenopausal ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % ) Leukocytes &gt; = 3,000/uL Absolute neutrophil count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin within normal institutional limit AST/ALT = &lt; 2.5 time institutional upper limit normal Serum creatinine within normal institutional limit Not pregnant nursing Negative pregnancy test Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation No history allergic reaction attribute compound similar chemical biologic composition green tea extract ( Polyphenon E ) , green tea food product supplement contain EGCG No history gastrointestinal bleeding include , limited , follow : Diverticulosis ; Peptic ulcer disease ; Erosive gastritis ; Varices No uncontrolled significant comorbid illness include , limited , follow : active serious infection require intravenous antibiotic ; symptomatic congestive heart failure ; unstable angina pectoris ; cardiac arrhythmia ; active gastrointestinal bleeding ; active liver disease ; psychiatric illness/social situation would limit compliance study requirement No active malignancy , except squamous cell carcinoma skin ; basal cell carcinoma skin ; carcinoma situ ; stage IA IB invasive squamous cell carcinoma cervix treat surgery and/or radiation therapy ; stage IA grade 1 adenocarcinoma endometrium treat surgery At least 6 month since prior chemotherapy , radiation therapy , and/or breast surgery No prior radiation therapy implant contralateral breast More 30 day since prior concurrent medication , herb , vitamin mineral supplement contain tea compound caffeine At least 30 day since prior concurrent investigational agent At least 30 day since prior concurrent tea consumption Willing limit regular coffee consumption = &lt; three 8ounce cup per day 30 day prior baseline evaluation study intervention Total daily caffeine consumption exceed 375 mg/day No concurrent hormone replacement therapy , tamoxifen , raloxifene Concurrent oral contraceptive allow provide dose change least 6 month prior study entry No concurrent chemotherapy radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>